Tissue samples from fetal hearts, pediatric dilated cardiomyopathy patients, and non-failing hearts showed differences in MCP1 activation consistent with HF progression (ANOVA, p value = 0.04), with the strongest difference observed between fetal and non-failing hearts (t test, adj. Here, CCL2 is linked to dilated cardiomyopathy.